Insomnia Market to Register Sustainable Growth During the Forecast Period (2022-2032) – DelveInsight | Key Companies – Taisho, Janssen, Imbrium, Merck, Idorsia, Eisai, Currax, Neurim, Vanda Pharma

Insomnia Market to Register Sustainable Growth During the Forecast Period (2022-2032) - DelveInsight | Key Companies - Taisho, Janssen, Imbrium, Merck, Idorsia, Eisai, Currax, Neurim, Vanda Pharma
Delveinsight Business Research LLP
As per DelveInsight’s assessment, the Insomnia Market size was USD 5,662.2 million in 2021, which is expected to grow immensely by 2032. The United States accounts for the largest market size of insomnia in comparison to EU4 (Germany, Italy, France, and Spain) and the UK, and Japan.

The Insomnia Market is anticipated to increase owing to rising awareness about insomnia, the increasingly diagnosed prevalent population of insomnia in the 7MM, and the entry of new products. The pipeline for Insomnia is dynamic, consisting of Vornorexant (TS-142), HETLIOZ (tasimelteon), Seltorexant (JNJ-42847922), Sunobinop (IMB-115), Piromelatine (Neu-P11), and Defined CBD (cannabidiol) some of which are expected to be launched during the forecast period [2022-2032].

DelveInsight’s “Insomnia Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Insomnia market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Insomnia market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Insomnia Market

Insomnia: An Overview

Insomnia is a common sleep-wake disorder characterized by both nocturnal and diurnal symptoms. It involves a predominant complaint of dissatisfaction with sleep quality or duration. It is accompanied by difficulties initiating sleep at bedtime, frequent or prolonged awakenings, or early-morning awakening with an inability to return to sleep.

There is no single established cause of insomnia. However, research suggests that in many people, it results from certain physiological arousal at unwanted times, disrupting standard sleep patterns. Such arousal can include a heightened heart rate, a higher body temperature, and increased levels of specific hormones like cortisol. It also often occurs along with various mental disorders. American Academy of Sleep Medicine categorizes insomnia into short-term, chronic, and other.

Insomnia Market Key Facts

  • The market size of Insomnia in the seven major markets was approximately USD 5,662.2 million in 2021.

  • The market size in the 7MM will increase at a CAGR of 3.7% due to increasing awareness of the disease

  • Among the 7MM countries, the US accounted for the highest market size of Insomnia, with approximately USD 4,606.0 million in 2021.

  • Among EU4 and the UK, France accounted for the highest market share of insomnia with approximately USD 348.2 million in 2021, followed by Germany with approximately USD 130.2 million in the respective year, while Spain accounted for the lowest market with USD 80.8 million in 2021.

  • Japan accounted for approximately USD 289.6 million in 2021, which is expected to increase by 2032.

  • In 2021, the total diagnosed prevalent cases of insomnia were estimated to be approximately 85,968,021 cases in the 7MM. These cases are expected to increase by 2032 at a CAGR of 0.6% during the study period (2019–2032).

  • Among the 7MM, the United States accounted for nearly 67% of the total diagnosed prevalent cases of insomnia in the year 2021. These cases are expected to increase further during the study period (2019–2032).

  • As per DelveInsight analysis, there were approximately 31,564,128 cases of acute insomnia in the US and 26,086,057 cases of chronic insomnia in 2021.

  • According to estimates based on DelveInsight’s epidemiology model of insomnia, in 2021, in EU4 and the UK, there were approximately 9,836,407 cases of acute insomnia and 13,305,555 cases of chronic insomnia, which are expected to increase by 2032.

Insomnia Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Insomnia market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Insomnia market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Insomnia Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders. 

The Report Covers the Insomnia Epidemiology, Segmented as –

  • Total Diagnosed Prevalent Cases of Insomnia in the 7MM [2019–2032]

  • Gender-specific cases of Insomnia in the 7MM [2019–2032]

  • Type-specific cases of Insomnia in the 7MM [2019–2032]

  • Age-specific cases of Insomnia in the 7MM [2019–2032]

Insomnia Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Insomnia market or expected to be launched during the study period. The analysis covers the Insomnia market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Insomnia pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Insomnia Market Will Evolve and Grow by 2032 @

Insomnia Therapeutics Analysis

The goal of therapy for insomnia is to improve the patient’s ability to fall asleep, stay asleep, wake and function well. According to various guidelines, insomnia is primarily treated using behavioral and psychological therapies such as CBT-I. Various pharmacological therapies, such as benzodiazepines or a combination of psychologic and pharmacologic therapies, are also recommended to ameliorate the condition. Several pharma and biotech giants are actively working in the Insomnia therapeutics domain to improve the treatment scenario further. 

The Leading Companies in the Insomnia Therapeutics Market Include:

  • Currax Pharmaceuticals

  • Defined Research

  • Eisai

  • Idorsia Pharmaceuticals

  • Imbrium Therapeutics

  • Janssen Pharmaceutical

  • Merck

  • Neurim Pharmaceuticals

  • Taisho Pharmaceutical

  • Vanda Pharmaceuticals

And Many Others

Insomnia Emerging and Marketed Drugs Covered in the Report Include:

  • Vornorexant (TS-142): Taisho Pharmaceutical

  • Seltorexant (JNJ-42847922): Janssen Pharmaceutical

  • Sunobinop (IMB-115): Imbrium Therapeutics

  • HETLIOZ (tasimelteon): Vanda Pharmaceuticals

  • Defined CBD (cannabidiol): Defined Research

  • BELSOMRA (suvorexant): Merck

  • QUVIVIQ (daridorexant): Idorsia Pharmaceuticals

  • DAYVIGO (lemborexant): Eisai

  • SILENOR (doxepin): Currax Pharmaceuticals

  • CIRCADIN: Neurim Pharmaceuticals

  • SLENYTO: Neurim Pharmaceuticals

And Many More

The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Insomnia Competitive Intelligence Analysis

4. Insomnia Market Overview at a Glance

5. Insomnia Disease Background and Overview

6. Insomnia Patient Journey

7. Insomnia Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Insomnia Treatment Algorithm, Current Treatment, and Medical Practices

9. Insomnia Unmet Needs

10. Key Endpoints of Insomnia Treatment

11. Insomnia Marketed Products

12. Insomnia Emerging Drugs and Latest Therapeutic Advances

13. Insomnia Seven Major Market Analysis

14. Attribute Analysis

15. Insomnia Market Outlook (In US, EU5, and Japan)

16. Insomnia Access and Reimbursement Overview

17. KOL Views on the Insomnia Market

18. Insomnia Market Drivers

19. Insomnia Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download the Sample PDF to Learn More About the Key Offerings of the Report @


Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic and evolving healthcare market today @ Healthcare Partner Identification

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States